Eruptive Keratoacanthomas After Nivolumab Treatment of Stage III Melanoma

Cutis. 2023 May;111(5):E13-E15. doi: 10.12788/cutis.0775.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Cutaneous Malignant Melanoma
  • Humans
  • Ipilimumab
  • Keratoacanthoma* / chemically induced
  • Keratoacanthoma* / diagnosis
  • Melanoma* / drug therapy
  • Nivolumab / adverse effects
  • Skin Neoplasms* / chemically induced
  • Skin Neoplasms* / drug therapy

Substances

  • Nivolumab
  • Ipilimumab